An App‐Based Proton Pump Inhibitor Discontinuation Tool: A Multicentre, Open‐Label, Randomised Superiority Trial
United European Gastroenterology Journal · 2026-10 · 14 (8)
DOI: 10.1002/ueg2.70297 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 18.10.2026. Verfasst von Lieke M Koggel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Mobile Applications, Proton Pump Inhibitors, Deprescriptions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Proton pump inhibitors (PPIs) are frequently used without long‐term indication. Discontinuation remains challenging because of rebound symptoms. Whether digital guidance tools improve discontinuation is unknown. We evaluated whether an app improves PPI discontinuation.
Methods
In this open‐label adaptive randomised controlled superiority trial, adults using daily PPI for ≥ 4 weeks without chronic PPI indication, according to the Dutch College of General Practitioners guideline, were recruited from outpatient clinics of Internal Medicine, Gastroenterology, Rheumatology and Nephrology departments at three Dutch hospitals. Patients were excluded if their physician deemed PPI use necessary beyond guideline recommendations, after prior upper gastrointestinal surgery, in case of inability to understand the study, unavailability of a smartphone/tablet, or limited life expectancy. Patients were randomly assigned (1:1), stratified by department and initial indication, to receive information on PPI discontinuation through an app (intervention) or brochure (control). Primary outcome was PPI discontinuation at 2 months follow‐up, defined as self‐declared intake of ≤ 1 tablet in the preceding 14 days. Sample‐size was revised earlier than prespecified based on interim data. The trial is registered as closed to accrual at ClinicalTrials.gov (NCT05348252).
Results
Between May 15, 2022, and March 31, 2023, 174 patients were randomized (86 intervention, 88 control). Nine and two patients, respectively, did not receive the allocated intervention. Of the 163 participants (mean age 54 y/o [SD 11], 76 males [47%]), 66/77 (86%) discontinued PPIs in the intervention group versus 55/86 (64%) in the control group (RR 1.34, 95% CI 1.11–1.61, p = 0.002). Adverse events occurred in 18/121 (15%) patients who discontinued PPI use and in 6/42 (14%) who did not. Only 4/121 (3%) and 1/42 (2%), respectively, were potentially attributable to PPI discontinuation.
Conclusion
An app‐based intervention significantly improves discontinuation of inappropriate PPI use compared with an information brochure and could therefore be considered for PPI deprescribing initiatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands.
- Interactive Studios, 's-Hertogenbosch, the Netherlands.
- IQ Health Science Department, Radboud University Medical Centre, Nijmegen, the Netherlands.
- Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands.
ORCID-Profile: Lieke M Koggel, Thomas Timmers, Marten A Lantinga, Rudolf B Kool, Cornelis Kramers, Peter D Siersema
Zitieren
APA
Koggel, L. M., Timmers, T., Lantinga, M. A., Kool, R. B., Kramers, C., van Herwaarden, N., Siersema, P. D., & SUPPORT study consortium (2026). An App‐Based Proton Pump Inhibitor Discontinuation Tool: A Multicentre, Open‐Label, Randomised Superiority Trial. United European Gastroenterology Journal, 14(8). https://doi.org/10.1002/ueg2.70297
Vancouver
Koggel LM, Timmers T, Lantinga MA, Kool RB, Kramers C, van Herwaarden N, et al. An App‐Based Proton Pump Inhibitor Discontinuation Tool: A Multicentre, Open‐Label, Randomised Superiority Trial. United European Gastroenterology Journal. 2026;14(8). doi:10.1002/ueg2.70297
BibTeX
@article{Koggel2026,
author = {Koggel, Lieke M and Timmers, Thomas and Lantinga, Marten A and Kool, Rudolf B and Kramers, Cornelis and van Herwaarden, Noortje and Siersema, Peter D and SUPPORT study consortium, SUPPORT study consortium},
title = {An App‐Based Proton Pump Inhibitor Discontinuation Tool: A Multicentre, Open‐Label, Randomised Superiority Trial},
journal = {United European Gastroenterology Journal},
year = {2026},
volume = {14},
number = {8},
doi = {10.1002/ueg2.70297}
}
EUVIMED